Nvidia-Backed Drug Developer Targets $159 Million IPO

Nvidia-backed Iambic Therapeutics is targeting a $159 million IPO, testing investor appetite for AI-powered biotechnology and its potential to transform drug development.

AI-powered drug discovery is heading for Wall Street as Iambic Therapeutics seeks to raise up to $159.4 million in a US initial public offering.

The biotechnology company, backed by Nvidia, is targeting a valuation of approximately $806 million as it develops cancer treatments using artificial intelligence.

The listing comes as investors look for practical applications of AI beyond chatbots and data centres.

Drug development is expensive, lengthy and uncertain. Iambic's technology aims to accelerate the discovery process, potentially reducing costs and improving efficiency.

For investors, the IPO offers exposure to two high-growth industries: artificial intelligence and biotechnology.

The investor takeaway: Iambic's market debut could provide an early indication of how much investors are willing to pay for AI-driven drug discovery, particularly when clinical results remain uncertain.